Scynexis Prepares To Launch Brexafemme In Vaginal Yeast Infections, Priced At $475
The first-in-class, novel antifungal for vaginal yeast infections will enter a genericized market, but also one with strong demand for better therapeutic options.
The first-in-class, novel antifungal for vaginal yeast infections will enter a genericized market, but also one with strong demand for better therapeutic options.